If approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Source: https://www.cnbc.com/2024/06/10/fda-adv ... nemab.html
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval
